0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global FIC Single-target Drugs Market Research Report 2026
Published Date: 2026-03-05
|
Report Code: QYRE-Auto-15K17940
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global FIC Single target Drugs Market Research Report 2024
BUY CHAPTERS

Global FIC Single-target Drugs Market Research Report 2026

Code: QYRE-Auto-15K17940
Report
2026-03-05
Pages:134
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

FIC Single-target Drugs Market

The global FIC Single-target Drugs market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on FIC Single-target Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
FIC (First in Class) refers to a drug that is first-in-class and is created by gradually synthesizing candidate compounds from scratch by finding new drug targets, mechanisms of action, and molecular structures. Through repeated trials and screening, the drug is ultimately found to meet the requirements of both therapeutic effects and human safety (tolerance, pharmacokinetics).
The North American market for FIC Single-target Drugs is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for FIC Single-target Drugs is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of FIC Single-target Drugs include Pfizer, Johnson & Johnson, Merck, Roche, Novartis, BMS, ImmunoGen, Sanofi, Immunocore, Genentech, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global FIC Single-target Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding FIC Single-target Drugs. The FIC Single-target Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global FIC Single-target Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist FIC Single-target Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of FIC Single-target Drugs Market Report

Report Metric Details
Report Name FIC Single-target Drugs Market
Segment by Type
  • RORγ Covalent Inhibitors
  • Citron Inhibitors
  • ALK2 Inhibitors
  • GCN2 Agonists
  • Others
by Application
  • Hospital
  • Clinic
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Pfizer, Johnson & Johnson, Merck, Roche, Novartis, BMS, ImmunoGen, Sanofi, Immunocore, Genentech, Eli Lilly, Agios, Boehringer Ingelheim, Gilead, Mallinckrodt, Phathom, Dermavant Sciences, Polarean lmaging, Marinus
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for FIC Single-target Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines FIC Single-target Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the FIC Single-target Drugs Market report?

Ans: The main players in the FIC Single-target Drugs Market are Pfizer, Johnson & Johnson, Merck, Roche, Novartis, BMS, ImmunoGen, Sanofi, Immunocore, Genentech, Eli Lilly, Agios, Boehringer Ingelheim, Gilead, Mallinckrodt, Phathom, Dermavant Sciences, Polarean lmaging, Marinus

What are the Application segmentation covered in the FIC Single-target Drugs Market report?

Ans: The Applications covered in the FIC Single-target Drugs Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the FIC Single-target Drugs Market report?

Ans: The Types covered in the FIC Single-target Drugs Market report are RORγ Covalent Inhibitors, Citron Inhibitors, ALK2 Inhibitors, GCN2 Agonists, Others

1 FIC Single-target Drugs Market Overview
1.1 Product Definition
1.2 FIC Single-target Drugs by Type
1.2.1 Global FIC Single-target Drugs Market Value by Type: 2025 vs 2032
1.2.2 RORγ Covalent Inhibitors
1.2.3 Citron Inhibitors
1.2.4 ALK2 Inhibitors
1.2.5 GCN2 Agonists
1.2.6 Others
1.3 FIC Single-target Drugs by Application
1.3.1 Global FIC Single-target Drugs Market Value by Application: 2025 vs 2032
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global FIC Single-target Drugs Market Size Estimates and Forecasts
1.4.1 Global FIC Single-target Drugs Revenue 2021–2032
1.4.2 Global FIC Single-target Drugs Sales 2021–2032
1.4.3 Global FIC Single-target Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 FIC Single-target Drugs Market Competition by Manufacturers
2.1 Global FIC Single-target Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global FIC Single-target Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global FIC Single-target Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of FIC Single-target Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of FIC Single-target Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of FIC Single-target Drugs, Product Types and Applications
2.7 Global Key Manufacturers of FIC Single-target Drugs, Date of Entry into the Industry
2.8 Global FIC Single-target Drugs Market Competitive Situation and Trends
2.8.1 Global FIC Single-target Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global FIC Single-target Drugs Players Market Share by Revenue
2.8.3 Global FIC Single-target Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global FIC Single-target Drugs Market Scenario by Region
3.1 Global FIC Single-target Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global FIC Single-target Drugs Sales by Region: 2021–2032
3.2.1 Global FIC Single-target Drugs Sales by Region: 2021–2026
3.2.2 Global FIC Single-target Drugs Sales by Region: 2027–2032
3.3 Global FIC Single-target Drugs Revenue by Region: 2021–2032
3.3.1 Global FIC Single-target Drugs Revenue by Region: 2021–2026
3.3.2 Global FIC Single-target Drugs Revenue by Region: 2027–2032
3.4 North America FIC Single-target Drugs Market Facts & Figures by Country
3.4.1 North America FIC Single-target Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America FIC Single-target Drugs Sales by Country (2021–2032)
3.4.3 North America FIC Single-target Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe FIC Single-target Drugs Market Facts & Figures by Country
3.5.1 Europe FIC Single-target Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe FIC Single-target Drugs Sales by Country (2021–2032)
3.5.3 Europe FIC Single-target Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific FIC Single-target Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific FIC Single-target Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific FIC Single-target Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific FIC Single-target Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America FIC Single-target Drugs Market Facts & Figures by Country
3.7.1 Latin America FIC Single-target Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America FIC Single-target Drugs Sales by Country (2021–2032)
3.7.3 Latin America FIC Single-target Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa FIC Single-target Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa FIC Single-target Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa FIC Single-target Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa FIC Single-target Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global FIC Single-target Drugs Sales by Type (2021–2032)
4.1.1 Global FIC Single-target Drugs Sales by Type (2021–2026)
4.1.2 Global FIC Single-target Drugs Sales by Type (2027–2032)
4.1.3 Global FIC Single-target Drugs Sales Market Share by Type (2021–2032)
4.2 Global FIC Single-target Drugs Revenue by Type (2021–2032)
4.2.1 Global FIC Single-target Drugs Revenue by Type (2021–2026)
4.2.2 Global FIC Single-target Drugs Revenue by Type (2027–2032)
4.2.3 Global FIC Single-target Drugs Revenue Market Share by Type (2021–2032)
4.3 Global FIC Single-target Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global FIC Single-target Drugs Sales by Application (2021–2032)
5.1.1 Global FIC Single-target Drugs Sales by Application (2021–2026)
5.1.2 Global FIC Single-target Drugs Sales by Application (2027–2032)
5.1.3 Global FIC Single-target Drugs Sales Market Share by Application (2021–2032)
5.2 Global FIC Single-target Drugs Revenue by Application (2021–2032)
5.2.1 Global FIC Single-target Drugs Revenue by Application (2021–2026)
5.2.2 Global FIC Single-target Drugs Revenue by Application (2027–2032)
5.2.3 Global FIC Single-target Drugs Revenue Market Share by Application (2021–2032)
5.3 Global FIC Single-target Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Company Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Pfizer FIC Single-target Drugs Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Johnson & Johnson
6.2.1 Johnson & Johnson Company Information
6.2.2 Johnson & Johnson Description and Business Overview
6.2.3 Johnson & Johnson FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Johnson & Johnson FIC Single-target Drugs Product Portfolio
6.2.5 Johnson & Johnson Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Merck FIC Single-target Drugs Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Roche
6.4.1 Roche Company Information
6.4.2 Roche Description and Business Overview
6.4.3 Roche FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Roche FIC Single-target Drugs Product Portfolio
6.4.5 Roche Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Company Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Novartis FIC Single-target Drugs Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 BMS
6.6.1 BMS Company Information
6.6.2 BMS Description and Business Overview
6.6.3 BMS FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 BMS FIC Single-target Drugs Product Portfolio
6.6.5 BMS Recent Developments/Updates
6.7 ImmunoGen
6.7.1 ImmunoGen Company Information
6.7.2 ImmunoGen Description and Business Overview
6.7.3 ImmunoGen FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 ImmunoGen FIC Single-target Drugs Product Portfolio
6.7.5 ImmunoGen Recent Developments/Updates
6.8 Sanofi
6.8.1 Sanofi Company Information
6.8.2 Sanofi Description and Business Overview
6.8.3 Sanofi FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Sanofi FIC Single-target Drugs Product Portfolio
6.8.5 Sanofi Recent Developments/Updates
6.9 Immunocore
6.9.1 Immunocore Company Information
6.9.2 Immunocore Description and Business Overview
6.9.3 Immunocore FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Immunocore FIC Single-target Drugs Product Portfolio
6.9.5 Immunocore Recent Developments/Updates
6.10 Genentech
6.10.1 Genentech Company Information
6.10.2 Genentech Description and Business Overview
6.10.3 Genentech FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Genentech FIC Single-target Drugs Product Portfolio
6.10.5 Genentech Recent Developments/Updates
6.11 Eli Lilly
6.11.1 Eli Lilly Company Information
6.11.2 Eli Lilly Description and Business Overview
6.11.3 Eli Lilly FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Eli Lilly FIC Single-target Drugs Product Portfolio
6.11.5 Eli Lilly Recent Developments/Updates
6.12 Agios
6.12.1 Agios Company Information
6.12.2 Agios Description and Business Overview
6.12.3 Agios FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Agios FIC Single-target Drugs Product Portfolio
6.12.5 Agios Recent Developments/Updates
6.13 Boehringer Ingelheim
6.13.1 Boehringer Ingelheim Company Information
6.13.2 Boehringer Ingelheim Description and Business Overview
6.13.3 Boehringer Ingelheim FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Boehringer Ingelheim FIC Single-target Drugs Product Portfolio
6.13.5 Boehringer Ingelheim Recent Developments/Updates
6.14 Gilead
6.14.1 Gilead Company Information
6.14.2 Gilead Description and Business Overview
6.14.3 Gilead FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Gilead FIC Single-target Drugs Product Portfolio
6.14.5 Gilead Recent Developments/Updates
6.15 Mallinckrodt
6.15.1 Mallinckrodt Company Information
6.15.2 Mallinckrodt Description and Business Overview
6.15.3 Mallinckrodt FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Mallinckrodt FIC Single-target Drugs Product Portfolio
6.15.5 Mallinckrodt Recent Developments/Updates
6.16 Phathom
6.16.1 Phathom Company Information
6.16.2 Phathom Description and Business Overview
6.16.3 Phathom FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Phathom FIC Single-target Drugs Product Portfolio
6.16.5 Phathom Recent Developments/Updates
6.17 Dermavant Sciences
6.17.1 Dermavant Sciences Company Information
6.17.2 Dermavant Sciences Description and Business Overview
6.17.3 Dermavant Sciences FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.17.4 Dermavant Sciences FIC Single-target Drugs Product Portfolio
6.17.5 Dermavant Sciences Recent Developments/Updates
6.18 Polarean lmaging
6.18.1 Polarean lmaging Company Information
6.18.2 Polarean lmaging Description and Business Overview
6.18.3 Polarean lmaging FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.18.4 Polarean lmaging FIC Single-target Drugs Product Portfolio
6.18.5 Polarean lmaging Recent Developments/Updates
6.19 Marinus
6.19.1 Marinus Company Information
6.19.2 Marinus Description and Business Overview
6.19.3 Marinus FIC Single-target Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.19.4 Marinus FIC Single-target Drugs Product Portfolio
6.19.5 Marinus Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 FIC Single-target Drugs Industry Chain Analysis
7.2 FIC Single-target Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 FIC Single-target Drugs Production Mode & Process Analysis
7.4 FIC Single-target Drugs Sales and Marketing
7.4.1 FIC Single-target Drugs Sales Channels
7.4.2 FIC Single-target Drugs Distributors
7.5 FIC Single-target Drugs Customer Analysis
8 FIC Single-target Drugs Market Dynamics
8.1 FIC Single-target Drugs Industry Trends
8.2 FIC Single-target Drugs Market Drivers
8.3 FIC Single-target Drugs Market Challenges
8.4 FIC Single-target Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global FIC Single-target Drugs Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global FIC Single-target Drugs Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global FIC Single-target Drugs Market Competitive Situation by Manufacturers in 2025
 Table 4. Global FIC Single-target Drugs Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global FIC Single-target Drugs Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global FIC Single-target Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global FIC Single-target Drugs Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market FIC Single-target Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of FIC Single-target Drugs, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of FIC Single-target Drugs, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of FIC Single-target Drugs, Product Types and Applications
 Table 12. Global Key Manufacturers of FIC Single-target Drugs, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global FIC Single-target Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on FIC Single-target Drugs Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global FIC Single-target Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global FIC Single-target Drugs Sales by Region (K Units), 2021–2026
 Table 18. Global FIC Single-target Drugs Sales Market Share by Region (2021–2026)
 Table 19. Global FIC Single-target Drugs Sales by Region (K Units), 2027–2032
 Table 20. Global FIC Single-target Drugs Sales Market Share by Region (2027–2032)
 Table 21. Global FIC Single-target Drugs Revenue by Region (US$ Million), 2021–2026
 Table 22. Global FIC Single-target Drugs Revenue Market Share by Region (2021–2026)
 Table 23. Global FIC Single-target Drugs Revenue by Region (US$ Million), 2027–2032
 Table 24. Global FIC Single-target Drugs Revenue Market Share by Region (2027–2032)
 Table 25. North America FIC Single-target Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America FIC Single-target Drugs Sales by Country (K Units), 2021–2026
 Table 27. North America FIC Single-target Drugs Sales by Country (K Units), 2027–2032
 Table 28. North America FIC Single-target Drugs Revenue by Country (US$ Million), 2021–2026
 Table 29. North America FIC Single-target Drugs Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe FIC Single-target Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe FIC Single-target Drugs Sales by Country (K Units), 2021–2026
 Table 32. Europe FIC Single-target Drugs Sales by Country (K Units), 2027–2032
 Table 33. Europe FIC Single-target Drugs Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe FIC Single-target Drugs Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific FIC Single-target Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific FIC Single-target Drugs Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific FIC Single-target Drugs Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific FIC Single-target Drugs Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific FIC Single-target Drugs Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America FIC Single-target Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America FIC Single-target Drugs Sales by Country (K Units), 2021–2026
 Table 42. Latin America FIC Single-target Drugs Sales by Country (K Units), 2027–2032
 Table 43. Latin America FIC Single-target Drugs Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America FIC Single-target Drugs Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa FIC Single-target Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa FIC Single-target Drugs Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa FIC Single-target Drugs Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa FIC Single-target Drugs Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa FIC Single-target Drugs Revenue by Country (US$ Million), 2027–2032
 Table 50. Global FIC Single-target Drugs Sales (K Units) by Type (2021–2026)
 Table 51. Global FIC Single-target Drugs Sales (K Units) by Type (2027–2032)
 Table 52. Global FIC Single-target Drugs Sales Market Share by Type (2021–2026)
 Table 53. Global FIC Single-target Drugs Sales Market Share by Type (2027–2032)
 Table 54. Global FIC Single-target Drugs Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global FIC Single-target Drugs Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global FIC Single-target Drugs Revenue Market Share by Type (2021–2026)
 Table 57. Global FIC Single-target Drugs Revenue Market Share by Type (2027–2032)
 Table 58. Global FIC Single-target Drugs Price (US$/Unit) by Type (2021–2026)
 Table 59. Global FIC Single-target Drugs Price (US$/Unit) by Type (2027–2032)
 Table 60. Global FIC Single-target Drugs Sales (K Units) by Application (2021–2026)
 Table 61. Global FIC Single-target Drugs Sales (K Units) by Application (2027–2032)
 Table 62. Global FIC Single-target Drugs Sales Market Share by Application (2021–2026)
 Table 63. Global FIC Single-target Drugs Sales Market Share by Application (2027–2032)
 Table 64. Global FIC Single-target Drugs Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global FIC Single-target Drugs Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global FIC Single-target Drugs Revenue Market Share by Application (2021–2026)
 Table 67. Global FIC Single-target Drugs Revenue Market Share by Application (2027–2032)
 Table 68. Global FIC Single-target Drugs Price (US$/Unit) by Application (2021–2026)
 Table 69. Global FIC Single-target Drugs Price (US$/Unit) by Application (2027–2032)
 Table 70. Pfizer Company Information
 Table 71. Pfizer Description and Business Overview
 Table 72. Pfizer FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Pfizer FIC Single-target Drugs Product
 Table 74. Pfizer Recent Developments/Updates
 Table 75. Johnson & Johnson Company Information
 Table 76. Johnson & Johnson Description and Business Overview
 Table 77. Johnson & Johnson FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. Johnson & Johnson FIC Single-target Drugs Product
 Table 79. Johnson & Johnson Recent Developments/Updates
 Table 80. Merck Company Information
 Table 81. Merck Description and Business Overview
 Table 82. Merck FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Merck FIC Single-target Drugs Product
 Table 84. Merck Recent Developments/Updates
 Table 85. Roche Company Information
 Table 86. Roche Description and Business Overview
 Table 87. Roche FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Roche FIC Single-target Drugs Product
 Table 89. Roche Recent Developments/Updates
 Table 90. Novartis Company Information
 Table 91. Novartis Description and Business Overview
 Table 92. Novartis FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. Novartis FIC Single-target Drugs Product
 Table 94. Novartis Recent Developments/Updates
 Table 95. BMS Company Information
 Table 96. BMS Description and Business Overview
 Table 97. BMS FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. BMS FIC Single-target Drugs Product
 Table 99. BMS Recent Developments/Updates
 Table 100. ImmunoGen Company Information
 Table 101. ImmunoGen Description and Business Overview
 Table 102. ImmunoGen FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 103. ImmunoGen FIC Single-target Drugs Product
 Table 104. ImmunoGen Recent Developments/Updates
 Table 105. Sanofi Company Information
 Table 106. Sanofi Description and Business Overview
 Table 107. Sanofi FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 108. Sanofi FIC Single-target Drugs Product
 Table 109. Sanofi Recent Developments/Updates
 Table 110. Immunocore Company Information
 Table 111. Immunocore Description and Business Overview
 Table 112. Immunocore FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 113. Immunocore FIC Single-target Drugs Product
 Table 114. Immunocore Recent Developments/Updates
 Table 115. Genentech Company Information
 Table 116. Genentech Description and Business Overview
 Table 117. Genentech FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 118. Genentech FIC Single-target Drugs Product
 Table 119. Genentech Recent Developments/Updates
 Table 120. Eli Lilly Company Information
 Table 121. Eli Lilly Description and Business Overview
 Table 122. Eli Lilly FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 123. Eli Lilly FIC Single-target Drugs Product
 Table 124. Eli Lilly Recent Developments/Updates
 Table 125. Agios Company Information
 Table 126. Agios Description and Business Overview
 Table 127. Agios FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 128. Agios FIC Single-target Drugs Product
 Table 129. Agios Recent Developments/Updates
 Table 130. Boehringer Ingelheim Company Information
 Table 131. Boehringer Ingelheim Description and Business Overview
 Table 132. Boehringer Ingelheim FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 133. Boehringer Ingelheim FIC Single-target Drugs Product
 Table 134. Boehringer Ingelheim Recent Developments/Updates
 Table 135. Gilead Company Information
 Table 136. Gilead Description and Business Overview
 Table 137. Gilead FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 138. Gilead FIC Single-target Drugs Product
 Table 139. Gilead Recent Developments/Updates
 Table 140. Mallinckrodt Company Information
 Table 141. Mallinckrodt Description and Business Overview
 Table 142. Mallinckrodt FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 143. Mallinckrodt FIC Single-target Drugs Product
 Table 144. Mallinckrodt Recent Developments/Updates
 Table 145. Phathom Company Information
 Table 146. Phathom Description and Business Overview
 Table 147. Phathom FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 148. Phathom FIC Single-target Drugs Product
 Table 149. Phathom Recent Developments/Updates
 Table 150. Dermavant Sciences Company Information
 Table 151. Dermavant Sciences Description and Business Overview
 Table 152. Dermavant Sciences FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 153. Dermavant Sciences FIC Single-target Drugs Product
 Table 154. Dermavant Sciences Recent Developments/Updates
 Table 155. Polarean lmaging Company Information
 Table 156. Polarean lmaging Description and Business Overview
 Table 157. Polarean lmaging FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 158. Polarean lmaging FIC Single-target Drugs Product
 Table 159. Polarean lmaging Recent Developments/Updates
 Table 160. Marinus Company Information
 Table 161. Marinus Description and Business Overview
 Table 162. Marinus FIC Single-target Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 163. Marinus FIC Single-target Drugs Product
 Table 164. Marinus Recent Developments/Updates
 Table 165. Key Raw Materials Lists
 Table 166. Raw Materials Key Suppliers Lists
 Table 167. FIC Single-target Drugs Distributors List
 Table 168. FIC Single-target Drugs Customers List
 Table 169. FIC Single-target Drugs Market Trends
 Table 170. FIC Single-target Drugs Market Drivers
 Table 171. FIC Single-target Drugs Market Challenges
 Table 172. FIC Single-target Drugs Market Restraints
 Table 173. Research Programs/Design for This Report
 Table 174. Key Data Information from Secondary Sources
 Table 175. Key Data Information from Primary Sources
 Table 176. Authors List of This Report


List of Figures
 Figure 1. Product Picture of FIC Single-target Drugs
 Figure 2. Global FIC Single-target Drugs Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global FIC Single-target Drugs Market Share by Type: 2025 & 2032
 Figure 4. RORγ Covalent Inhibitors Product Picture
 Figure 5. Citron Inhibitors Product Picture
 Figure 6. ALK2 Inhibitors Product Picture
 Figure 7. GCN2 Agonists Product Picture
 Figure 8. Others Product Picture
 Figure 9. Global FIC Single-target Drugs Market Value by Application (US$ Million), 2021–2032
 Figure 10. Global FIC Single-target Drugs Market Share by Application: 2025 & 2032
 Figure 11. Hospital
 Figure 12. Clinic
 Figure 13. Other
 Figure 14. Global FIC Single-target Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 15. Global FIC Single-target Drugs Market Size (US$ Million), 2021–2032
 Figure 16. Global FIC Single-target Drugs Sales (K Units), 2021–2032
 Figure 17. Global FIC Single-target Drugs Average Price (US$/Unit), 2021–2032
 Figure 18. FIC Single-target Drugs Report Years Considered
 Figure 19. FIC Single-target Drugs Sales Share by Manufacturers in 2025
 Figure 20. Global FIC Single-target Drugs Revenue Share by Manufacturers in 2025
 Figure 21. Top 5 and Top 10 Global FIC Single-target Drugs Players: Market Share by Revenue in FIC Single-target Drugs in 2025
 Figure 22. FIC Single-target Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 23. Global FIC Single-target Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 24. North America FIC Single-target Drugs Sales Market Share by Country (2021–2032)
 Figure 25. North America FIC Single-target Drugs Revenue Market Share by Country (2021–2032)
 Figure 26. United States FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 27. Canada FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. Europe FIC Single-target Drugs Sales Market Share by Country (2021–2032)
 Figure 29. Europe FIC Single-target Drugs Revenue Market Share by Country (2021–2032)
 Figure 30. Germany FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. France FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. U.K. FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Italy FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Russia FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Asia Pacific FIC Single-target Drugs Sales Market Share by Region (2021–2032)
 Figure 36. Asia Pacific FIC Single-target Drugs Revenue Market Share by Region (2021–2032)
 Figure 37. China FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Japan FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. South Korea FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. India FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Australia FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. China Taiwan FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Southeast Asia FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Latin America FIC Single-target Drugs Sales Market Share by Country (2021–2032)
 Figure 45. Latin America FIC Single-target Drugs Revenue Market Share by Country (2021–2032)
 Figure 46. Mexico FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Brazil FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 48. Argentina FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 49. Colombia FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Middle East and Africa FIC Single-target Drugs Sales Market Share by Country (2021–2032)
 Figure 51. Middle East and Africa FIC Single-target Drugs Revenue Market Share by Country (2021–2032)
 Figure 52. Turkey FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 53. Saudi Arabia FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 54. UAE FIC Single-target Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Global Sales Market Share of FIC Single-target Drugs by Type (2021–2032)
 Figure 56. Global Revenue Market Share of FIC Single-target Drugs by Type (2021–2032)
 Figure 57. Global FIC Single-target Drugs Price (US$/Unit) by Type (2021–2032)
 Figure 58. Global Sales Market Share of FIC Single-target Drugs by Application (2021–2032)
 Figure 59. Global Revenue Market Share of FIC Single-target Drugs by Application (2021–2032)
 Figure 60. Global FIC Single-target Drugs Price (US$/Unit) by Application (2021–2032)
 Figure 61. FIC Single-target Drugs Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS